Risk of cardiovascular diseases associated with oral progestagen preparations with therapeutic indications

Lancet. 1999 Nov 6;354(9190):1610. doi: 10.1016/s0140-6736(99)03132-3.

Abstract

Data from the WHO Collaborative Study suggest that use of progestagen preparations with therapeutic indications are associated with a significantly increased risk of venous thromboembolism but not stroke or myocardial infarction.

Publication types

  • Comment
  • Letter

MeSH terms

  • Adult
  • Case-Control Studies
  • Contraceptives, Oral, Synthetic / adverse effects*
  • Female
  • Humans
  • Logistic Models
  • Middle Aged
  • Myocardial Infarction / chemically induced
  • Odds Ratio
  • Progesterone Congeners / adverse effects*
  • Progesterone Congeners / therapeutic use
  • Risk Factors
  • Stroke / chemically induced
  • Thromboembolism / chemically induced*
  • World Health Organization

Substances

  • Contraceptives, Oral, Synthetic
  • Progesterone Congeners